NHSは3年間の段階的な肥満薬Mounjaroの導入を計画し,複数の健康状態の25万人を対象としています. NHS plans a 3-year phased rollout of obesity drug Mounjaro, targeting 250,000 patients with multiple health conditions.
NHSは3年間で25万人を対象に 肥満薬Mounjaroを段階的に導入する予定です The NHS plans a phased rollout of the obesity drug Mounjaro, also known as tirzepatide, over three years, targeting 250,000 patients. 肥満に伴う多重な健康状態の患者を優先します Initially, it will prioritize those with multiple health conditions linked to obesity. 臨床試験では,この薬で36週間にわたって平均21%の体重減少が示され,血糖管理にも役立ちます. Clinical trials showed an average weight loss of 21% over 36 weeks with the drug, which also assists with blood sugar management. 医療・ケア・エクセレンス国立研究所は 最終的なガイドラインを出す前に提案を審査します The National Institute for Health and Care Excellence will review the proposals before final guidance is issued.